SMARCA4 and neoplasm: We then correlated the first quartile (<111 H‐score) versus the other three quartiles (≥111 H‐score) for SMARCA4 and the fourth quartile (>170 H‐score) versus the first three quartiles (≤170 H‐score) for SMARCE1 with the clinicopathological patient characteristics, in order to test a possible oncogenic influence of SMARCE1 and a potential tumor‐suppressing function of SMARCA4.